From: Genetics of Prostate Cancer (PDQ®)
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Table 3. BRCA Pathogenic Variants in Prostate Cancera
| Population | Number of Studies | Fixed-Effect Pooled Prostate Cancer RR (95% CI) | Random-Effect Pooled Prostate Cancer RR (95% CI) | I2 |
|---|---|---|---|---|
| BRCA1 | ||||
| All | 20 | 1.57 (1.30–1.91) | 1.69 (1.30–2.20) | 30% |
| Unselected for age, aggressive prostate cancer, or prostate cancer family history | 15 | 1.43 (1.71–1.75) | 1.47 (1.13–1.91) | 25% |
| Unselected for age, aggressive prostate cancer, or prostate cancer family history and did not use historical controls | 13 | 1.32 (1.07–1.64) | 1.33 (1.05–1.69) | 8% |
| Prostate cancer diagnosed <65 y | 4 | 2.21 (1.47–3.30) | 2.19 (1.21–3.98) | 57% |
| Prostate cancer diagnosed >65 y | 3 | 1.18 (0.83–1.70) | 1.43 (0.71–2.87) | 65% |
| BRCA2 | ||||
| All | 21 | 5.24 (4.63–5.49) | 3.94 (2.79–5.56) | 83% |
| Unselected for age, aggressive prostate cancer, or prostate cancer family history | 15 | 3.87 (3.34–4.47) | 3.33 (2.57–4.33) | 58% |
| Prostate cancer diagnosed <65 y | 5 | 6.37 (4.81–8.43) | 5.28 (3.10–9.00) | 63% |
| Prostate cancer diagnosed >65 y | 3 | 3.74 (2.82–4.96) | 3.74 (2.82–4.96) | 0% |
CI = confidence interval; RR = relative risk.
aAdapted from Nyberg et al.